Long-term zidovudine therapy HIV-associated Kaposi sarcoma clinical consequences side effects Interferon alpha IFN-alpha effective HIV-associated KS patients Zidovudine beneficial AIDS patients drugs inhibitory effect HIV replication IFN-alpha zidovudine treatment HIV-associated KS order tolerance clinical efficacy homosexual men HIV-associated KS open trial IU second day mg/d Treatment first month patients subjective intolerance others severe opportunistic infections HIV-cachexia Fifteen evaluable patients combination treatment period months average months dosage drug-induced cytotoxicity Complete remission patients partial remission stable disease progression overall response rate Negative expression treatment positive predictor extracutaneous involvement negative influence tumor remission patients mean initial T-helper cell count conclusion combination therapy AZT HIV-related Kaposi sarcoma patients contrast IFN-alpha patients immune systems combined treatment 